Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
About this item
Full title
Author / Creator
PROSPER Investigators , Sternberg, Cora N , Fizazi, Karim , Saad, Fred , Shore, Neal D , De Giorgi, Ugo , Penson, David F , Ferreira, Ubirajara , Efstathiou, Eleni , Madziarska, Katarzyna , Kolinsky, Michael P , Cubero, Daniel I. G , Noerby, Bettina , Zohren, Fabian , Lin, Xun , Modelska, Katharina , Sugg, Jennifer , Steinberg, Joyce and Hussain, Maha
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among men with high-risk, nonmetastatic, castration-resistant prostate cancer, the addition of enzalutamide to androgen-deprivation therapy improved overall survival by nearly a year as compared with ADT alone: median survival was 67 months with enzalutamide plus ADT and 56 months with ADT alone.
Alternative Titles
Full title
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Authors, Artists and Contributors
Author / Creator
Sternberg, Cora N
Fizazi, Karim
Saad, Fred
Shore, Neal D
De Giorgi, Ugo
Penson, David F
Ferreira, Ubirajara
Efstathiou, Eleni
Madziarska, Katarzyna
Kolinsky, Michael P
Cubero, Daniel I. G
Noerby, Bettina
Zohren, Fabian
Lin, Xun
Modelska, Katharina
Sugg, Jennifer
Steinberg, Joyce
Hussain, Maha
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_umu_176925
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_176925
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2003892
